Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

Gudiol, Carlota; Royo-Cebrecos, Cristina; Abdala, Edson; AKOVA, MURAT; Alvarez, Rocio; Maestro-de la Calle, Guillermo; Cano, Angela; Cervera, Carlos; Clemente, Wanessa; Martin-Davila, Pilar; Freifeld, Alison; Gomez, Lucia; Gottlieb, Thomas; Gurgui, Merce; Herrera, Fabian; Manzur, Adriana; Maschmeyer, Georg; Meije, Yolanda; Montejo, Miguel; Peghin, Maddalena; Rodriguez-Bano, Jesus; Ruiz-Camps, Isabel; Sukiennik, Teresa; Tebe, Cristian; Carratala, Jordi

doi:10.1128/aac.00164-17

Efficacy of beta-Lactam/beta-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-beta-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

Atıf İçin Kopyala

Gudiol C., Royo-Cebrecos C., Abdala E., AKOVA M. , Alvarez R., Maestro-de la Calle G., ...Daha Fazla

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, cilt.61, 2017 (SCI İndekslerine Giren Dergi)

Cilt numarası: 61 Konu: 8
Basım Tarihi: 2017
Doi Numarası: 10.1128/aac.00164-17
Dergi Adı: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Özet

beta-Lactam/beta-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum beta-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.